Daridorexant (Quviviq)

Primer

Daridorexant (Trade name: Quviviq) is a dual orexin receptor antagonist (DORA) used in the treatment of insomnia disorder.

Pharmacokinetics

See also article: Introduction to Pharmacology

Pharmacokinetics of Daridorexant

Absorption
Distribution
Metabolism
Elimination
Half-life

See also article: Cytochrome (CYP) P450 Metabolism

Daridorexant: Cytochrome P450 Metabolism

Substrate of (Metabolized by)
Induces
Inhibits

Pharmacodynamics

Mechanism of Action

Toxicity

Indications

Dosing

Dosing for Daridorexant

Starting	25 mg PO daily
Titration
Maximum	50 mg PO daily
Taper

Formulations

Daridorexant comes in

Monitoring

Contraindications

Absolute

Relative

Drug-Drug Interactions

Side Effects

Adverse Events

Clinical Pearls

Daridorexant, like all DORAs, have a theoretical risk for abuse.^[1]^[2]
- Patients with a history of abuse or addiction may be at increased risk for abuse and addiction to DORAs and should be followed carefully

Special Populations

Geriatric

See main article: Geriatric Pharmacology

Pediatric

See main article: Pediatric Pharmacology

Obstetric and Fetal

See main article: Obstetric and Fetal Pharmacology

Medically Ill

See main article: Psychotropic Dosing in the Medically Ill

Resources

¹⁾ FDA Review, Lemborexant, Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology

²⁾ Ufer, M., Kelsh, D., Schoedel, K. A., & Dingemanse, J. (2021). Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep.

Table of Contents